Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
PTCT Price Action
Last 7 days
2.8%
Last 30 days
10.1%
Last 90 days
31.0%
Trailing 12 Months
71.0%
PTCT RSI Chart
PTCT Valuation
PTCT Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
PTCT Fundamentals
PTCT Revenue
PTCT Earnings
PTCT Profitability
PTCT Investor Care
PTCT Alerts
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 1.8B | 1.8B | 0 | 0 |
| 2024 | 927.6M | 900.5M | 900.7M | 806.8M |
| 2023 | 770.4M | 818.7M | 798.2M | 937.8M |
| 2022 | 569.4M | 618.2M | 696.6M | 698.8M |
| 2021 | 430.4M | 471.9M | 492.2M | 538.6M |
| 2020 | 321.7M | 311.4M | 358.4M | 380.8M |
| 2019 | 261.8M | 278.5M | 296.4M | 307.0M |
| 2018 | 203.7M | 224.5M | 236.3M | 264.2M |
| 2017 | 90.3M | 122.5M | 141.3M | 174.1M |
| 2016 | 48.2M | 57.0M | 70.2M | 82.7M |
| 2015 | 23.5M | 28.6M | 36.7M | 36.8M |
| 2014 | 36.8M | 31.6M | 17.0M | 25.2M |
| 2013 | 28.6M | 27.8M | 36.9M | 34.7M |
| 2012 | 113.1M | 115.9M | 36.7M | 33.9M |
| 2011 | 0 | 0 | 0 | 105.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| CEO | Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS |
|---|---|
| WEBSITE | ptcbio.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 1402 |
